Orchid Pharma Ltd Board Approves Unaudited Q1 FY27 Results
Orchid Pharma Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the unaudited financial results for the first quarter of the Financial Year 2026-27, ending June 30, 2026. The results, which were subject to a limited review by statutory auditors M/s. Singhi & Co., were presented on both standalone and consolidated bases. The company also noted the amalgamation with Dhanuka Laboratories Limited, effective July 10, 2026, with an appointed date of April 01, 2024, impacting the restatement of financial results. Additionally, the company completed the acquisition of assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS, consolidating global ownership of Enmetazobactam.
Key Highlights
- Board approved unaudited Q1 FY27 financial results.
- Results presented on standalone and consolidated basis.
- Amalgamation with Dhanuka Laboratories effective July 10, 2026.
- Acquisition of Allecra Therapeutics assets completed.
- Statutory auditors provided an unmodified review conclusion.
Price Impact
More from ORCHPHARMA